•
Mar 31, 2023
Journey Medical Q1 2023 Earnings Report
Reported financial results and corporate highlights for Q1 2023.
Key Takeaways
Journey Medical reported total revenues of $12.2 million for the first quarter of 2023, with net product revenues impacted by higher gross-to-net adjustments and lower unit sales volumes for certain products, although an improvement was seen in April.
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023.
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29.
Expecting a return to revenue growth for the remainder of 2023.
Anticipate further reductions in SG&A expenses, resulting in annual savings exceeding $12.0 million compared to 2022.
Journey Medical
Journey Medical
Forward Guidance
Journey Medical anticipates a return to revenue growth for the remainder of 2023 and further reductions in SG&A expenses.